Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Phase II Lung Metcore - Preoperative Metformin for Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Metformin

First Posted Date: 2017-03-22

Last Posted Date: 2020-08-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 28

Registration Number: NCT03086733

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Failure Rate of GLyburide And Metformin Among Gestational Diabetics

Phase 4

Withdrawn

Conditions: Gestational Diabetes Mellitus, Class A2

Interventions: Drug: Glyburide
Drug: Metformin

First Posted Date: 2017-03-13

Last Posted Date: 2018-05-04

Lead Sponsor: The University of Texas Health Science Center, Houston

Registration Number: NCT03078725

Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Pharynx
Larynx
LIP
Oral Cavity

Interventions: Drug: Metformin +Doxycycline
Drug: Metformin Hydrochloride
Drug: Doxycycline

First Posted Date: 2017-03-10

Last Posted Date: 2018-12-24

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 7

Registration Number: NCT03076281

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Not Applicable

Conditions: Tyrosine Kinase Mutation
EGFR Gene Mutation
Non-Small Cell Adenocarcinoma

Interventions: Drug: TKI
Drug: Metformin

First Posted Date: 2017-03-07

Last Posted Date: 2017-03-07

Lead Sponsor: Instituto Nacional de Cancerologia de Mexico

Target Recruit Count: 120

Registration Number: NCT03071705

Locations: 🇲🇽
Instituto National de Cancerologia, Mexico, Mexico

Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers

Phase 1

Completed

Conditions: Aging

Interventions: Drug: Sirolimus
Drug: Diclofenac
Drug: Metformin

First Posted Date: 2017-03-07

Last Posted Date: 2019-04-01

Lead Sponsor: Anne Chang

Target Recruit Count: 10

Registration Number: NCT03072485

Locations: 🇺🇸
Stanford Dermatology, Redwood City, California, United States

Antidiabetic Effects on Intrahepatic Fat

Phase 4

Completed

Conditions: Non-Alcoholic Fatty Liver Disease
Type2 Diabetes

Interventions: Drug: Liraglutide
Drug: Metformin
Drug: Gliclazide

First Posted Date: 2017-03-01

Last Posted Date: 2017-03-01

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 87

Registration Number: NCT03068065

Locations: 🇨🇳
at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Sotagliflozin (SAR439954)
Drug: Metformin
Drug: Sulfonylurea

First Posted Date: 2017-02-28

Last Posted Date: 2021-05-11

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 507

Registration Number: NCT03066830

Locations: 🇪🇪
Investigational Site Number 2333003, Parnu, Estonia
🇧🇬
Investigational Site Number 1003002, Ruse, Bulgaria
🇺🇦
Investigational Site Number 8043002, Kyiv, Ukraine

and more 73 locations